Søgning på udtrykket 'influenza' giver 49 resultater
Dokumenter [3] Sider [2] Kalender [3] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [3]
Version 8 (21.11.22) Udarbejdet af Dansk Selskab for Infektionsmedicin i samarbejde med Dansk Selskab for Klinisk Mikrobiologi, Dansk Hæmatologisk Selskab, Dansk Pædiatrisk Selskab, Dansk Selskab for Almen Medicin, Dansk Lungemedicinsk Selskab, Dansk Selskab for Obstetrik og Gynækologi, Dansk Transplantationsselskab, Dansk Selskab for Klinisk Onkologi & Fagligt Selskab for Hygiejnesygeplejersker
Bl.a. om HIV, hepatitis, influenza og CNS infektioner
Sider [2]
…nti-TNF-alfa (2011), Tjekliste ved screening før behandling med anti-TNF-alpha, Indvandrermedicin: Chalotte Stecher (tovholder), Hanne Nødgaard Christensen, Christian Wejse, Jane Agergaard, Morten Sodemann og Marie Nørredam Influenza: Jens Lundgren (tovholder), Thomas Benfield, Jan Gerstoft, Isik Johansen, Gitte Kronborg, Henrik Nielsen, Lene Surland Knudsen, Merete Storgaard og Ole Kirk Influenza, Meningitis og encephalitis: Christian Brandt (tovholder), …
Risikoen for bakteriel infektion og sepsis er svært forhøjet ved manglende miltfunktion som følge af splenektomi samt kongenit eller funktionel aspleni. Alvorlige infektioner skyldes primært Streptococcus pneumoniae, Haemophilus influenzae og Neisseria meningitidis. Risikoen for svær infektion ved malaria og dyrebid er også markant forhøjet. Vaccination, antibiotika profylakse/tidlig behandling og adækvat patient information er afgørende for forebyggelse af infektioner. Antibiotika behandlin…
…der kan smitte gennem upasteuriseret mælk omfatter som bekendt bl.a. brucella, Mycobacterium bovis, Listeria, Q-feber, HEV og TBE. Men nu er også influenza på listen. Udover de vidtrækkende konsekvenser, som fugleinfluenza-infektioner kan have i husdyrhold, så er det altså også nu en sygdom på listen over infektiøse agens, der smitter gennem upasteuriseret ko-mælk. Heldigvis ser det ud til at pasteurisering er effektiv, og det skal også bemærkes, at i artiklen har man kun set på katte og mus.
Kalender [3]
19. april, Statens Serum Institut
24. januar 2019, Aarhus Universitetshospital
9. november 2018, Korsør
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Emerg Microbes Infect
10.09.2024
Volume 13, Issue 1, December 2024 .
BMC Infectious Diseases
10.09.2024
. Abstract. The neurological complications of influenza affect mainly the pediatric Asian population. In the category of influenza-associated encephalopathy, acute necrotizing encephalopathy (ANE) is a rapidly progressive and fulminant brain disorder associated with significant neurological sequelae and mortality. To date, only a few adult cases of influenza-associated ANE have been reported. We describe a 44-year-old woman who presented with rapid progression of cons…
Virulence
8.09.2024
Volume 15, Issue 1, December 2024 .
Emerg Microbes Infect
7.09.2024
Volume 13, Issue 1, December 2024 .
Lancet Infectious Diseases
6.09.2024
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
BMC Infectious Diseases
5.09.2024
. Abstract. . Background. On March 16th 2024, the first case of Human infection with avian influenza H10N3 since the end of the global COVID-19 Pandemic was reported in Kunming, China. To enhance comprehension of the source of infection and risk factors of the H10N3 virus infection, this case report summarizes the clinical features, epidemiological investigation, and laboratory test results. Provides recommendations for the …
Emerg Microbes Infect
3.09.2024
Volume 13, Issue 1, December 2024 .
Emerg Microbes Infect
1.09.2024
Volume 13, Issue 1, December 2024 .
Nature
30.08.2024
BMC Infectious Diseases
29.08.2024
…ct. . Objective. At different times, public health faces various challenges and the degree of intervention measures varies. The research on the impact and prediction of meteorology factors on influenza is increasing gradually, however, there is currently no evidence on whether its research results are affected by different periods. This study aims to provide limited evidence to reveal this issue. . . . …
Lancet Respiratory Medicine
29.08.2024
Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) are increasingly recognised as important complications in patients requiring intensive care for severe viral pneumonia. The diagnosis can typically be made in 10–20% of patients with severe influenza or COVID-19, but only when appropriate diagnostic tools are used. Bronchoalveolar lavage sampling for culture, galactomannan testing, and PCR forms the cornerstone of diagnosis, whereas visual examinatio…
Emerg Microbes Infect
25.08.2024
Volume 13, Issue 1, December 2024 .
Clinical Microbiology and Infection
24.08.2024
High-dose quadrivalent influenza vaccine (HD-QIV) was introduced during the 2021/22 influenza season in France for adults aged ≥65 years as an alternative to standard-dose quadrivalent influenza vaccines (SD-QIV). The aim of this study is to estimate the relative vaccine effectiveness (rVE) of HD-QIV versus SD-QIV against influenza-related hospitalisations in France.
Journal of Infectious Diseases
24.08.2024
Abstract . Background . An unmet need exists for effective antivirals to treat patients hospitalized with influenza. The results of 2 Phase 3 studies evaluating the efficacy and safety of pimodivir in combination with investigator-chosen standard-of-care (SoC) treatment are presented.Methods . Hospitalized patients (hospital study; NCT03376321) and high-risk outpatients (outpatient study; NCT03381196) with laboratory-confirmed influenza A infection were randomized 1:1 to 600 mg pimodivir twice daily (BID) +…
Lancet
23.08.2024
In hospitalised patients with severe influenza, oseltamivir and peramivir might reduce duration of hospitalisation compared with standard care or placebo, although the certainty of evidence is low. The effects of all antivirals on mortality and other important patient outcomes are very uncertain due to scarce data from randomised controlled trials.
Lancet
23.08.2024
Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir probably decreases the risk of symptomatic seasonal influenza in individuals at high risk for severe disease after exposure to seasonal influenza viruses. Post-exposure prophylaxis with zanamivir, oseltamivir, laninamivir, or baloxavir might reduce the risk of symptomatic zoonotic influenza after exposure to novel influenza A viruses associated with severe disease in infected humans.
Journal of Medical Virology
22.08.2024
Journal of Medical Virology, Volume 96, Issue 8, August 2024.
Clinical Infectious Diseases
21.08.2024
Abstract . Background . Influenza causes substantial morbidity, particularly among older individuals. Updated data on the effectiveness of currently licensed vaccines in this population are needed.Methods . At Kaiser Permanente Southern California, we conducted a retrospective cohort study to evaluate comparative vaccine effectiveness (cVE) of high-dose (HD), adjuvanted, and standard-dose (SD) cell-based influenza vaccines, relative to the SD egg-based vaccine. We included adults aged ≥65 years who receiv…
Emerg Microbes Infect
19.08.2024
Volume 13, Issue 1, December 2024 .
PLoS One Infectious Diseases
16.08.2024
…on, and feeding percentage, potential supplementary factors such as cholesterol, polyamine, galactose, pluronic-F68, glucose, L-glutamine, and ZnSO4 were screened for Spodoptera frugiperda (Sf9) cell culture and expression of hemagglutinin (HA) protein of Influenza virus via Placket-Burman design and then optimized through Box-Behnken approach. The optimized conditions were then applied for scale-up culture and the expressed r-HA protein was characterized. Optimization of selected parameters via the Box-Beh…
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Morbidity and Mortality Weekly Report (MMWR)
29.08.2024
This report describes the first known cluster of U.S. human influenza A(H5) cases.
Morbidity and Mortality Weekly Report (MMWR)
27.08.2024
This report provides new CDC recommendations for the upcoming flu season.
Morbidity and Mortality Weekly Report (MMWR)
16.08.2024
This report describes four cases of nontypeable Haemophilus disease that occurred at an elementary school in Detroit, Michigan.
Eurosurveillance latest updates
2.08.2024
. Background. Healthcare personnel (HCP) are at high risk for respiratory infections through occupational exposure to respiratory viruses. . . Aim. We used data from a prospective influenza vaccine effectiveness study in HCP to quantify the incidence of acute respiratory infections (ARI) and their associated presenteeism and absenteeism. . . Methods. At the start and end of each season, HCP at two Israeli hospitals provided serum to screen for antibodies to influenza virus using the haemagglutination …
Eurosurveillance latest updates
26.07.2024
We investigated the thermostability of four European avian influenza A(H5N1) viruses in whole and semi-skimmed milk and their replication in bovine kidney and lung cells amid the current influenza A(H5N1) dairy cattle outbreak in the United States. Results showed strain-dependent differences in thermal inactivation, particularly in whole milk, and variable replication efficacy in lung cells. These findings support assessing the inactivation of European H5N1 viruses in milk and their replication in bovine ce…
Morbidity and Mortality Weekly Report (MMWR)
25.07.2024
This report describes symptom monitoring and testing among exposed dairy and poultry workers in Michigan during the H5N1 outbreak.
Eurosurveillance latest updates
22.06.2024
Highly pathogenic avian influenza (HPAI) has caused widespread mortality in both wild and domestic birds in Europe 2020–2023. In July 2023, HPAI A(H5N1) was detected on 27 fur farms in Finland. In total, infections in silver and blue foxes, American minks and raccoon dogs were confirmed by RT-PCR. The pathological findings in the animals include widespread inflammatory lesions in the lungs, brain and liver, indicating efficient systemic dissemination of the virus. Phylogenetic analysis of Finnish A(H5N1) …
Eurosurveillance latest updates
22.06.2024
.
Morbidity and Mortality Weekly Report (MMWR)
25.05.2024
This report describes the joint investigation between CDC, U.S. Department of Agriculture, and the Food and Drug Administration after influenza A (H5N1) was detected in a U.S. farm worker.
Medscape Infectious Diseases
18.05.2024
The U.S. Centers for Disease Control and Prevention (CDC) on Tuesday released data on influenza A found in wastewater in a public dashboard that could assist in tracking the. . Reuters Health Information
Eurosurveillance latest updates
26.04.2024
A severe outbreak of influenza A(H1N1pdm09) infection in seven children (median age: 52 months) occurred between December 2023 and January 2024 in Tuscany, Italy. Clinical presentation ranged from milder encephalopathy to acute necrotizing encephalopathy (ANE) with coma and multiorgan failure; one child died. This report raises awareness for clinicians to identify and treat early acute encephalopathy caused by H1N1 influenza and serves as a reminder of severe presentations of influenza in young children and…
Eurosurveillance latest updates
12.04.2024
…ropean Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season. .
Morbidity and Mortality Weekly Report (MMWR)
29.02.2024
This report describes estimated vaccine effectiveness for laboratory-confirmed flu in California.
Morbidity and Mortality Weekly Report (MMWR)
29.02.2024
This report describes estimates of 2023-24 influenza vaccine effectiveness among different age groups.
Eurosurveillance latest updates
23.02.2024
. Background. Waning immunity from seasonal influenza vaccination can cause suboptimal protection during peak influenza activity. However, vaccine effectiveness studies assessing waning immunity using vaccinated and unvaccinated individuals are subject to biases. . . Aim. We examined the association between time since vaccination and laboratory-confirmed influenza to assess the change in influenza vaccine protection over time. . . Methods. Using linked laboratory and health administrative databases in…
Eurosurveillance latest updates
23.02.2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were…
Eurosurveillance latest updates
16.02.2024
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS…
ECDC COVID-19 updates
15.02.2024
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
ECDC COVID-19 updates
6.02.2024
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
Eurosurveillance latest updates
26.01.2024
. Background. Influenza was almost absent for 2 years following the implementation of strict public health measures to prevent the spread of SARS-CoV-2. The consequence of this on infections in different age groups is not yet known. . . Aim. To describe the age groups infected with the influenza virus in 2021/22, the first post-pandemic influenza season in Denmark, compared with the previous six seasons, and subtypes circulating therein. . . Methods. Infection and hospitalisation incidences per season…